X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1149) 1149
Publication (75) 75
Book Review (20) 20
Newsletter (7) 7
Book Chapter (4) 4
Conference Proceeding (2) 2
Newspaper Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (790) 790
fenofibrate (647) 647
male (555) 555
index medicus (529) 529
female (443) 443
middle aged (394) 394
fenofibrate - therapeutic use (384) 384
hypolipidemic agents - therapeutic use (329) 329
fenofibrate - adverse effects (318) 318
pharmacology & pharmacy (273) 273
hypolipidemic agents - adverse effects (265) 265
aged (239) 239
adult (235) 235
animals (226) 226
cholesterol (205) 205
drug therapy, combination (199) 199
fenofibrate - pharmacology (188) 188
risk factors (171) 171
fenofibrate - administration & dosage (155) 155
coronary-heart-disease (148) 148
triglycerides - blood (146) 146
lipids (143) 143
treatment outcome (142) 142
dyslipidemias - drug therapy (139) 139
dyslipidemia (138) 138
statins (137) 137
hypolipidemic agents - pharmacology (133) 133
diabetes (129) 129
hyperlipidemias - drug therapy (126) 126
simvastatin (123) 123
hypolipidemic agents - administration & dosage (122) 122
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (119) 119
cardiac & cardiovascular systems (118) 118
triglycerides (117) 117
endocrinology & metabolism (116) 116
drug therapy (115) 115
research (111) 111
gemfibrozil (107) 107
therapy (107) 107
double-blind method (103) 103
risk (103) 103
fibric acids (102) 102
atorvastatin (101) 101
rats (98) 98
medicine, general & internal (95) 95
mice (94) 94
metabolic syndrome (91) 91
atherosclerosis (90) 90
cholesterol, ldl - blood (90) 90
lipids - blood (90) 90
cholesterol, hdl - blood (89) 89
care and treatment (88) 88
diabetes mellitus, type 2 - drug therapy (88) 88
type 2 diabetes (88) 88
cardiovascular-disease (85) 85
metabolism (83) 83
hyperlipidemia (82) 82
cholesterol - blood (80) 80
cardiovascular disease (76) 76
diabetes mellitus, type 2 - complications (76) 76
medicine & public health (75) 75
ppar-alpha (75) 75
type-2 diabetes-mellitus (75) 75
fenofibrate - analogs & derivatives (73) 73
health aspects (73) 73
fibrates (70) 70
drug interactions (69) 69
safety (69) 69
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (68) 68
ppar alpha - agonists (68) 68
analysis (66) 66
dosage and administration (65) 65
insulin resistance (65) 65
biochemistry & molecular biology (64) 64
cardiovascular diseases - prevention & control (63) 63
inflammation (63) 63
disease (62) 62
anticholesteremic agents - therapeutic use (61) 61
efficacy (61) 61
peripheral vascular disease (61) 61
density-lipoprotein cholesterol (60) 60
insulin-resistance (60) 60
low density lipoproteins (59) 59
cardiovascular diseases (58) 58
dose-response relationship, drug (58) 58
internal medicine (58) 58
liver (58) 58
medicine, research & experimental (58) 58
bezafibrate (57) 57
oxidative stress (57) 57
expression (56) 56
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (56) 56
cardiovascular (55) 55
hypertriglyceridemia - drug therapy (55) 55
micronized fenofibrate (55) 55
ezetimibe (54) 54
hypercholesterolemia - drug therapy (54) 54
liver - drug effects (54) 54
prevention (54) 54
glucose (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1078) 1078
French (41) 41
Spanish (14) 14
Russian (7) 7
Chinese (6) 6
German (4) 4
Japanese (3) 3
Italian (2) 2
Polish (2) 2
Czech (1) 1
Hungarian (1) 1
Persian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e99245
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic triglyceride accumulation, ranging from steatosis to steatohepatitis and cirrhosis. NAFLD... 
PPAR-ALPHA | LIPID-METABOLISM | ACID | RAT | FATTY LIVER-DISEASE | FENOFIBRATE | MULTIDISCIPLINARY SCIENCES | NONALCOHOLIC STEATOHEPATITIS | MICE | TYPE-2 DIABETES-MELLITUS | EXPRESSION | Humans | Male | Fatty Liver - chemically induced | Fenofibrate - adverse effects | Dose-Response Relationship, Drug | Fenofibrate - pharmacology | Hepatocytes - cytology | Hepatocytes - drug effects | Sterol Regulatory Element Binding Protein 1 - metabolism | Fatty Liver - genetics | Hypolipidemic Agents - adverse effects | Fatty Liver - metabolism | Mice, Inbred C57BL | Fenofibrate - administration & dosage | PPAR alpha - genetics | Hypolipidemic Agents - pharmacology | Hep G2 Cells | Triglycerides - metabolism | Gene Expression Regulation - drug effects | Animals | Sterol Regulatory Element Binding Protein 1 - genetics | Lipogenesis - drug effects | Hypolipidemic Agents - administration & dosage | Mice | PPAR alpha - metabolism | Drugs | Pathogenesis | Liver | Medical services | Staining | Lipids | Activation | Experiments | Accumulation | Risk factors | Fatty liver | Rodents | Hepatology | Sterol regulatory element-binding protein | Lipogenesis | Heart diseases | Drug dosages | Liver diseases | Health risks | Metabolic diseases | Metabolism | Gene expression | Electron microscopy | Steatosis | Medicine | Studies | Fenofibrate | Cirrhosis | Side effects | Hospitals | Diet | Clinical medicine | Cardiovascular diseases | Metabolic disorders | Endocrinology | Sterol regulatory element-binding protein 1c
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
Background & Aims We performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury (DILI) from licensed drugs... 
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | POPULATION | SUSCEPTIBILITY | RISK | TERBINAFINE | TICLOPIDINE | HEPATITIS | CLASS-I | HEPATOTOXICITY | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | ANTIGEN | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Gastroenterologi | Klinisk medicin
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 17, pp. 1563 - 1574
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 01/2018, Volume 233, Issue 1, pp. 153 - 161
Peroxisome proliferator‐activated receptors (PPARs) are ligand‐activated transcription factors involved in several physiological processes including modulation... 
cardiovascular disease | lipids | metabolism | peroxisome proliferator‐activated receptors | diabetes | therapy | peroxisome proliferator-activated receptors | INTIMA-MEDIA THICKNESS | METABOLIC SYNDROME | PHYSIOLOGY | RANDOMIZED CONTROLLED-TRIAL | SIMVASTATIN PLUS FENOFIBRATE | CELL BIOLOGY | INSULIN-RESISTANCE | ORAL FAT LOAD | PPAR-GAMMA AGONISTS | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | ALPHA/DELTA AGONIST GFT505 | Hypoglycemic Agents - therapeutic use | Peroxisome Proliferator-Activated Receptors - agonists | Hypolipidemic Agents - adverse effects | Humans | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Animals | Anti-Inflammatory Agents - adverse effects | Signal Transduction - drug effects | Peroxisome Proliferator-Activated Receptors - metabolism | Anti-Inflammatory Agents - therapeutic use | Ligands | Hypolipidemic Agents - therapeutic use | Hypoglycemic Agents - adverse effects | Physiological aspects | Carbohydrate metabolism | Drugs | Physiological effects | Transcription factors | Dyslipidemia | Differentiation (biology) | Lipids | Training | Proteins | Receptors | Atherosclerosis | Tumorigenesis | Blood pressure | Lipid metabolism | Heart diseases | Sensitizing | Carbohydrates | Pioglitazone | Diabetes mellitus | Coagulants | Metabolism | Insulin | Arteriosclerosis | Fibrosis | Rosiglitazone | Clinical medicine | Peroxisome proliferator-activated receptors | Index Medicus
Journal Article
8.